Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Summary

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

Timeline

Start

2025-01-08

Primary completion

2026-08-31

Completion

2026-12-31

Drugs

Indications